FINNENCE ▪ THE WIRE FILE
THE WIRE · № 72939
News■ Unclear/unknown
HealthWorX Offers Employers a Safer Path to Lower Healthcare Costs as IRS Scrutiny of 105(b) Schemes Grows
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-09 12:31 UTC
LAST UPDATE2026-10-09 12:31 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A TPA's marketing stance on IRS scrutiny signals compliance risk for tax-advantaged health plans, not a tradable catalyst.
Compliance marketing, no direct market transmission
CATALYST TO WATCH
IRS guidance on 105(b) arrangements
MAIN RISK
Unproven claims about scheme legality
FULL DISPATCH
Nonprofit third-party administrator urges employers to choose transparent, compliant savings over tax-engineered workarounds and commission-driven advice OXNARD, Calif., Oct. 9, 2026 /PRNewswire/ -- HealthWorX, a nonprofit third-party administrator (TPA), is calling on employers to...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
CONTEXTHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Iambic sets IPO terms, seeking $150 million to advance AI-designed cancer drugs2026-10-09 11:15 UTC
Iambic sets IPO terms, seeking $150 million to advance AI-designed cancer drugs2026-10-09 11:15 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2) — Viking Therapeutics, Inc.2026-10-09 12:00 UTC
New Phase 3 trial: Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2) — Viking Therapeutics, Inc.2026-10-09 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma — Pfizer2026-10-09 12:00 UTC
New Phase 3 trial: A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma — Pfizer2026-10-09 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: Phase 3 Study of Intravitreal 4D-150 in Adults With Diabetic Macular Edema (DME) (4D-150-C005) — 4D Molecular Therapeutics2026-10-09 12:00 UTC
New Phase 3 trial: Phase 3 Study of Intravitreal 4D-150 in Adults With Diabetic Macular Edema (DME) (4D-150-C005) — 4D Molecular Therapeutics2026-10-09 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets — Trevi Therapeutics2026-10-09 12:00 UTC
New Phase 3 trial: Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets — Trevi Therapeutics2026-10-09 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) — Sanofi2026-10-09 12:00 UTC
Phase 3 results posted: Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) — Sanofi2026-10-09 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.